Study of Eye Insert Over 6 Months as a New Treatment for Uveitis

Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!

Open to people ages 18 years and up

• Male or non-pregnant female at least 18 years of age at time of consent
• One or both eyes having a history of recurrent non-infectious uveitis affecting the posterior segment of the eye (intermediate, posterior, or panuveitis) with or without anterior uveitis > 1 year duration.
• During the 52 weeks prior to enrollment (Day 1), the study eye has either received treatment systemic corticosteroid or other systemic therapies given for at least 12 weeks, and/or at least 2 intra- or peri-ocular injections of corticosteroid for management of uveitis OR the study eye has experienced recurrence recurrences of uveitis at least 2 separate times requiring systemic, intra- or peri-ocular injection of corticosteroid.
• Subject is not planning to undergo elective ocular surgery during the study
• Subject has ability to understand and sign the Informed Consent Form (ICF).
• Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
• Other protocol-specified inclusion criteria may apply.

• History of posterior uveitis only that is not accompanied by vitritis or macular edema.
• History of iritis only associated with no vitreous cells, anterior chamber cells, or vitreous haze at Day 1.
• Uveitis with infectious etiology.
• Vitreous hemorrhage.
• Intraocular inflammation associated with a condition other than noninfectious uveitis (eg, intraocular lymphoma).
• Uveitis limited to the anterior segment, ie, anterior uveitis only.
• Ocular malignancy in either eye, including choroidal melanoma.
• Previous viral retinitis.
• Requirement for chronic systemic or inhaled corticosteroid therapy (>15mg prednisone daily) or chronic systemic immunosuppressive therapy.
• History of certain skin cancers (specifically, basal cell carcinoma and squamous cell carcinoma), any malignancy receiving treatment, or in remission less than 5 years prior to Day 1.
• Positive test for human immunodeficiency virus (HIV) or syphilis during Screening.
• Mycobacterial uveitis or chorioretinal changes of either eye which, in the opinion of the Investigator, result from infectious mycobacterial uveitis.
• Systemic infection within 30 days prior to Day 1.
• Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in the protocol from at least 14 days prior to Day 1 until the 52-week Visit.
• Other protocol-specified exclusion criteria may apply.